The Patent Finder
XT

Xlink Therapeutics, Inc.

First filing 2013
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Five patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Feb 2034. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2034
Next term end
5
Patent families

When these terms end

Each bar runs from grant to computed term end. 2018 to 2036.
US 10,111,853 Compounds, Compositions, and Methods for the Treatment of Cancers Feb 10, 2034
US 10,287,308 Compounds, Compositions, and Methods for the Treatment of Cancers Feb 10, 2034
US 10,472,380 Platinum Compounds Having a Heterocycle Ligand, Nanoparticles, and Uses Thereof Jul 16, 2034
US 10,322,137 Platinum Compounds, Compositions, and Uses Thereof Jun 23, 2035
US 10,342,801 Platinum Compounds, Compositions, and Uses Thereof Jun 22, 2036
20222026203020342036
Every computed term in this portfolio is shown above.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 18, 2026
    The maintenance fee for Platinum Compounds, Compositions, and Uses Thereof (US 10,322,137) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 1 fee due Jan 9, 2027
    The maintenance fee for Platinum Compounds, Compositions, and Uses Thereof (US 10,342,801) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
  • 1 fee due May 12, 2027
    The maintenance fee for Platinum Compounds Having a Heterocycle Ligand, Nanoparticles, and Uses Thereof (US 10,472,380) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 5 of 5

PatentTitleStatusExpiresConfidence
US 10,111,853Compounds, Compositions, and Methods for the Treatment of Cancers
Grace period ended
 · Low confidence
Grace period endedLow confidence
US 10,287,308Compounds, Compositions, and Methods for the Treatment of Cancers
In force
 · High confidence
In forceHigh confidence
US 10,472,380Platinum Compounds Having a Heterocycle Ligand, Nanoparticles, and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,322,137Platinum Compounds, Compositions, and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,342,801Platinum Compounds, Compositions, and Uses Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 5: 6 patents ended · 9 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited